We are a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize , is a platform that uses P-ethoxy, which is a deoxyribonucleic acid…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$11M
▲ +38.5% YoY
Op. Margin
–
ROIC
-2284.41%
▼ -2227.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
▲ +8.3% YoY
Op. Cash Flow (TTM)
-$4M
▲ +8.3% YoY
Net Debt
$479K
Cash & Equiv.
$0.00
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with BPTH
Bio-Path Holdings (BPTH) in three numbers
- Quality score
- 20/100
- Best check: share count change, -99.8%. Weakest: return on capital, -2284.4%.
- Quality
Questions about Bio-Path Holdings
Is Bio-Path Holdings (BPTH) overvalued?
Bio-Path Holdings trades at 0.00 times earnings. Intrinsiqq's fair value calculator has no opening value for BPTH, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Bio-Path Holdings a high-quality business?
Bio-Path Holdings scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is share count change at -99.8%, and its weakest is return on capital at -2284.4%. The Quality tab shows every check against its target.
Does Bio-Path Holdings (BPTH) pay a dividend?
No. Bio-Path Holdings (BPTH) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 20 May 2026 (period ending 31 Mar 2026), SEC. Price: last close 3 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BPTH's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BPTH
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.